English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Periodontal and peri-implant diseases are infection pathologies related to the pathogenicity of the microorganisms involved [1]. The worldwide practice of indiscriminate and continuous use of antibiotics for the control and prophylaxis of bacterial pathogens has led to the development of bacterial resistance to most available antimicrobials [2]. Concurrently, the rapid increase in bacterial resistance to currently available antimicrobial drugs has led researchers to search for new sources of molecules active against bacterial pathogens, outlining a new generation of anti-infective drug development. A promising approach for the development of a new generation of antimicrobial drugs has arisen from the studies of host-pathogen interactions, which prompted a shift of drug targets from bacterial survival to pathogenicity control. Examples of potential nonconventional targets for microbial control are molecules and receptors involved in bacterial adherence to biotic and abiotic surfaces as well as signal systems controlling bacterial group behaviour of populations organised in biofilms, such as quorum sensing (QS) [3]. In contrast to conventional antibiotics, antimicrobial drugs directed against such unconventional targets do not jeopardise bacterial survival, imposing a low selection pressure and thus avoiding the development of resistance [4]. Methods Here we analysed the effects of novel synthetic lactams, compounds derived from furanones which display recognized antibiofilm activity. Three synthetic lactams were tested against biofilm of Enterococcus faecalis grown over an implantable polymeric material (PLGA-HA). Inhibition assays of adhesion and biofilm formation, and SEM observation were used to quantify and qualify E. faecalis’ biofilm formation. To assay for biofilm inhibition, bacterial strains were grown statically for 20 h at 37°C in TSB. Polystyrene 96-well microtitre plates were inoculated with 100 μL/well of bacterial suspension previously diluted to 5 × 10 CFU/mL in TSB supplemented with 4% sucrose (w/v) and 3.5% (v/v) dimethyl sulphoxide (DMSO). Compounds to be tested for antibiofilm activity were prepared at a concentration of 175 μg/ml, in the same media as before, and added to the test wells. Biofilm inhibition capacity was assessed by CFU counting after bacterial disaggregation from the surfaces and microscopic analysis of the polymers. Cytotoxicity of the lactams against human fibroblasts and keratinocytes was tested, at four different concentrations (43,75; 87,5; 131,25 and 175 μg/ml), by MTT assay [5].

bmc proceedings

Effects of antibiofilm compounds on the cellular and bacterial colonization of polimeric surfaces: a step towards biofunctionalization of implantable devices